Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion type Assertion NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_head.
- NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion description "[We report data from a phase I/II, multicenter, open-label study of Korean patients with refractory KRAS wild-type adenocarcinoma NSCLC (defined as patients with evidence of disease progression during or within 6 months of treatment with chemotherapy and gefitinib or erlotinib).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_provenance.
- NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion evidence source_evidence_literature NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_provenance.
- NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion SIO_000772 25521398 NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_provenance.
- NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion wasDerivedFrom befree-2016 NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_provenance.
- NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_assertion wasGeneratedBy ECO_0000203 NP1249194.RAUZw2NZFUUG1z0T696FfAQjrtkyCVmnJpdz7tEjoiG_s130_provenance.